Centers for Medicare and Medicaid Services (CMS) Report Shows Slower Growth in Health Spending, Generic Medicines Critical to Cost Control, GPhA/IMS Health Data Affirms

Published Online: Monday, January 6, 2014
Follow Pharmacy_Times:
PRESS RELEASE

WASHINGTON, DC (January 6, 2014) — Today, the Centers for Medicare and Medicaid Services (CMS) issued findings that show slower growth in health spending since the implementation of the Affordable Care Act. This successful cost control is consistent with data demonstrating that savings from generic medicines are at an all-time high, reaching $217 billion in 2012 and $1.2 trillion over the most recent decade, according to the 2013 Report on Generic Drug Savings in the U.S., the fifth annual report compiled by IMS Health on behalf of the Generic Pharmaceutical Association (GPhA).

Overall national health expenditures grew at an annual rate of 3.7 percent in 2012, marking the fourth consecutive year of low growth, the Centers for Medicare & Medicaid Services (CMS) Office of the Actuary reported today. Health spending as a share of gross domestic product fell slightly from 17.3 percent in 2011 to 17.2 percent in 2012. These findings will appear in the January 2014 edition of Health Affairs.

“As 2014 witnesses extensive changes in the health landscape, the role of generic medicines in providing patient savings and access to affordable care is critical and unquestionable,” said Ralph G. Neas, President and CEO of the Generic Pharmaceutical Association. “A large proportion of patient and consumer savings is attributable to the increased use of generic medicines, and a decrease in overall spending on prescription drugs. So, it is more important than ever to make sure policy and practice align so that patients, state and federal government, the nation’s business community and others can continue to rely on generic medicines for relief from the high cost of health care.”

For the first time, this year’s GPhA report points to savings for each payer type (insurers, Medicaid, out-of-pocket and other third-party payers) at the retail level. In fact, enrollee savings from generics in Medicare Part D or other federal benefit plans totals $301 billion. For seniors enrolled in Part D, generic savings reached $180 billion since the program began in 2006. Patients paying out-of-pocket have saved $78 billion by purchasing generics over the recent decade.

Click here for the full GPhA 2013 Report on Generic Drug Savings in the U.S.

The full CMS report and press release are available here.
Related Articles
GPhA has agreed to support compromise automatic substitution legislation that would allow interchangeable biologics to be automatically substituted at the pharmacy. This step brings millions of Americans closer to the day when they will be able to access safe alternatives to costly biologic medicines. Indeed, Express Scripts projects savings of $250 billion in 10 years should only the 11 likeliest biosimilars enter the market.
“GPhA applauds FDA for taking helpful steps to address, and hopefully limit, scenarios in which some brand drug companies misuse Risk Evaluation and Mitigation Strategies programs to thwart competition from more affordable generic drugs. The ongoing abuse of REMS and REMS-like programs costs the American health system and its patients $5.4 billion annually, according to a study conducted by Matrix Global Advisors. Interestingly, as the United States market readies for biosimilars, this same study identifies $140 million in lost savings that would occur for every $1 billion in biologics sales.
Former House Speaker Newt Gingrich today told senior health care executives at an Academy of Managed Care Pharmacy forum that Congressional Republicans are weighing whether to “get into the death grip of Obamacare” or to wait out President Obama’s term seeking “specific, practical, doable reforms.”
The Generic Pharmaceutical Association announced that it has named Terry Bazyluk as Vice President for Communications, effective December 1, 2014.
Latest Issues
$auto_registration$